Acarbose
- Generic Name
- Acarbose
- Brand Names
- Precose
- Drug Type
- Small Molecule
- Chemical Formula
- C25H43NO18
- CAS Number
- 56180-94-0
- Unique Ingredient Identifier
- T58MSI464G
- Background
Acarbose is a complex oligosaccharide that acts as an inhibitor of several enzymes responsible for the breakdown of complex carbohydrates in the intestines. It inhibits both pancreatic alpha-amylase and membrane-bound alpha-glucosidases - including intestinal glucoamylase, sucrase, maltase, and isomaltase - which are responsible for the metabolism of complex...
- Indication
Acarbose is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
- Associated Conditions
- Type 2 Diabetes Mellitus
- Associated Therapies
- -
Metabolic Syndrome Risk Factor in IGT: STOP-NIDDM Trial
- First Posted Date
- 2008-03-05
- Last Posted Date
- 2008-03-07
- Lead Sponsor
- GWT-TUD GmbH
- Target Recruit Count
- 1429
- Registration Number
- NCT00629213
- Locations
- 🇩🇪
GWT-TUD GmbH, Dresden, Saxony, Germany
AI(I)DA Acarbose and the Subclinical Inflammation
- Conditions
- Interventions
- First Posted Date
- 2007-11-15
- Last Posted Date
- 2008-04-11
- Lead Sponsor
- GWT-TUD GmbH
- Target Recruit Count
- 104
- Registration Number
- NCT00558883
- Locations
- 🇩🇪
GWT-TUD GmbH; Centre for Clinical Studies, Dresden, Germany
Effects of Acarbose on Endothelial Function After a Mixed Meal in Newly Diagnosed Type 2 Diabetes
- First Posted Date
- 2007-11-01
- Last Posted Date
- 2013-03-01
- Lead Sponsor
- Technische Universität Dresden
- Registration Number
- NCT00551954
The Effects of Nateglinide and Acarbose on the Post-Prandial Glucose Control in Type 2 Diabetic Patients
- Conditions
- First Posted Date
- 2007-02-21
- Last Posted Date
- 2008-03-24
- Lead Sponsor
- Inje University
- Target Recruit Count
- 85
- Registration Number
- NCT00437918
- Locations
- 🇰🇷
Paik Diabetes Center, Pusan Paik Hospital, College of Medicine, Inje University, Busan, Korea, Republic of
🇰🇷Endocrinology and Metabolism, Maryknoll General Hospital, Busan, Korea, Republic of
Additional Glucose Lowering and Anti-Inflammatory Effects by Acarbose and Alcohol in Subjects With Impaired Glucose Tolerance or Mild Type 2 Diabetes
- Conditions
- First Posted Date
- 2007-01-04
- Last Posted Date
- 2007-01-04
- Lead Sponsor
- Taichung Veterans General Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT00417950
- Locations
- 🇨🇳
Taichung Veterans General Hospital, Taichung, Taiwan
Effects of Acarbose Versus Glibenclamide on MAGE and Oxidative Stress in Patients With Type 2 DM
- First Posted Date
- 2007-01-04
- Last Posted Date
- 2010-05-12
- Lead Sponsor
- Taichung Veterans General Hospital
- Target Recruit Count
- 51
- Registration Number
- NCT00417729
- Locations
- 🇨🇳
Taichung Veterans General Hospital, Taichung, Taiwan
Acarbose and Secondary Prevention After Coronary Stenting
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2009-06-25
- Target Recruit Count
- 300
- Registration Number
- NCT00221156
- Locations
- 🇯🇵
Kawasaki Medical School Hospital, Kurashiki, Okayama, Japan
🇯🇵Institute of Biomedical Research and Innovation., Kobe, Hyogo Pref., Japan
🇯🇵Kobe City General Hospital/Institute of Biomedical Research and Innovation, Kobe, Hyogo Pref., Japan
Treatment of Orthostatic Hypotension in Autonomic Failure
- Conditions
- Interventions
- Drug: AtomoxetineDrug: placeboDrug: AcarboseDevice: inflatable abdominal binder (sham)Drug: Pyridostigmine BromideDrug: YohimbineDrug: Midodrine HClDrug: ModafinilDrug: OctreotideOther: water intakeDrug: Diphenhydramine HydrochlorideDrug: Ranitidine HCLDrug: TranylcypromineDrug: Ergotamine/ CaffeineDrug: CelecoxibDrug: PseudoephedrineDrug: MethylphenidateDrug: IndomethacinDrug: IbuprofenDrug: Oxymetazoline 0.05% nasal solutionDietary Supplement: BovrilDrug: AcetazolamideDrug: Rivastigmine tartrateDrug: Carbidopa/levodopaDevice: Inflatable abdominal binder
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2017-01-18
- Lead Sponsor
- Vanderbilt University
- Target Recruit Count
- 389
- Registration Number
- NCT00223691
- Locations
- 🇺🇸
Vanderbilt University, Nashville, Tennessee, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.